Trials / Active Not Recruiting
Active Not RecruitingNCT05325073
Erythropoietin Therapy to Induce Regulatory T Cells in Liver Transplant Recipients
- Status
- Active Not Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- Northwestern University · Academic / Other
- Sex
- All
- Age
- 18 Years – 74 Years
- Healthy volunteers
- Not accepted
Summary
The hypothesis of this proof-of-concept study is that EPO increases the frequency, stability and/or function of Tregs in liver transplant recipients. We also hypothesize that EPO will have a greater effect in everolimus vs. tacrolimus treated LTR, thus providing the rationale for a subsequent clinical trial to utilize EPO in combination with everolimus as a more successful pathway toward tolerance.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Erythropoietin | Erythropoietin |
Timeline
- Start date
- 2022-02-18
- Primary completion
- 2023-05-23
- Completion
- 2024-09-30
- First posted
- 2022-04-13
- Last updated
- 2024-03-15
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05325073. Inclusion in this directory is not an endorsement.